Kinetics, cross-reactivity, and specificity of Bet v 1-specific IgG4 antibodies induced by immunotherapy with birch pollen

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 68, Issue 11, 2013, Pages 1377-1386

  Subbarayal, B ^a   Schiller, D ^b   Mobs C ^c   De Jong, N W ^d   Ebner, C ^e   Reider, N ^f   Bartel, D ^b   Lidholm, J ^g   Pfutzner W ^c   Gerth Van Wijk, R ^d   Vieths, S ^b   Bohle, B ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b PAUL EHRLICH INSTITUT   (Germany)

^c PHILIPPS UNIVERSITY MARBURG   (Germany)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e Allergy Clinic Reumannplatz   (Austria)

^f Universitatsklinik fuer Dermatologie und Venerologie Innsbruck   (Austria)

^g Thermo Fisher Scientific   (United States)

Author keywords

birch pollen allergy; blocking antibodies; IgE; IgG4; specific immunotherapy

Indexed keywords

BET V 1 ANTIBODY; EPITOPE; FOOD ALLERGEN; IMMUNOGLOBULIN ANTIBODY; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G4; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ALGORITHM; ANTIBODY SPECIFICITY; ANTIGEN BINDING; ARTICLE; BASOPHIL; BIRCH; CHILD; CROSS REACTION; HUMAN; IMMUNOTHERAPY; KINETICS; LYMPHOCYTE PROLIFERATION; POLLEN; PRIORITY JOURNAL; SCHOOL CHILD; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

BIRCH POLLEN ALLERGY; BLOCKING ANTIBODIES; IGE; IGG4; SPECIFIC IMMUNOTHERAPY;

ADOLESCENT; ADULT; ALLERGENS; ANTIBODIES, BLOCKING; ANTIBODY SPECIFICITY; ANTIGENS, PLANT; BETULA; CELL LINE; CHILD; CROSS REACTIONS; DESENSITIZATION, IMMUNOLOGIC; FOOD HYPERSENSITIVITY; HUMANS; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; MIDDLE AGED; POLLEN; YOUNG ADULT;

EID: 84887501840     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/all.12236     Document Type: Article

References (36)

1. Pauli G, Larsen TH, Rak S, Horak F, Pastorello E, Valenta R, et al. Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis. J Allergy Clin Immunol 2008; 122: 951-960.
2. Mobs C, Ipsen H, Mayer L, Slotosch C, Petersen A, Wurtzen PA, et al. Birch pollen immunotherapy results in long-term loss of Bet v 1-specific T(H)2 responses, transient T(R)1 activation, and synthesis of IgE-blocking antibodies. J Allergy Clin Immunol 2012; 130: 1108-1116.
3. Wurtzen PA, Lund G, Lund K, Arvidsson M, Rak S, Ipsen H,. A double-blind placebo-controlled birch allergy vaccination study II: correlation between inhibition of IgE binding, histamine release and facilitated allergen presentation. Clin Exp Allergy 2008; 38: 1290-1301.
4. Lalek N, Kosnik M, Silar M, Korosec P,. Immunoglobulin G-dependent changes in basophil allergen threshold sensitivity during birch pollen immunotherapy. Clin Exp Allergy 2010; 40: 1186-1193.
5. van Neerven RJ, Wikborg T, Lund G, Jacobsen B, Brinch-Nielsen A, Arnved J, et al. Blocking antibodies induced by specific allergy vaccination prevent the activation of CD4 + T cells by inhibiting serum-IgE-facilitated allergen presentation. J Immunol 1999; 163: 2944-2952.
6. Gajhede M, Osmark P, Poulsen FM, Ipsen H, Larsen JN, Joost van Neerven RJ, et al. X-ray and NMR structure of Bet v 1, the origin of birch pollen allergy. Nat Struct Biol 1996; 3: 1040-1045.
7. Mirza O, Henriksen A, Ipsen H, Larsen JN, Wissenbach M, Spangfort MD, et al. Dominant epitopes and allergic cross-reactivity: complex formation between a Fab fragment of a monoclonal murine IgG antibody and the major allergen from birch pollen Bet v 1. J Immunol 2000; 165: 331-338.
8. Spangfort MD, Mirza O, Ipsen H, Van Neerven RJ, Gajhede M, Larsen JN,. Dominating IgE-binding epitope of Bet v 1, the major allergen of birch pollen, characterized by X-ray crystallography and site-directed mutagenesis. J Immunol 2003; 171: 3084-3090.
9. Mittag D, Batori V, Neudecker P, Wiche R, Friis EP, Ballmer-Weber BK, et al. A novel approach for investigation of specific and cross-reactive IgE epitopes on Bet v 1 and homologous food allergens in individual patients. Mol Immunol 2006; 43: 268-278.
10. Jahn-Schmid B, Radakovics A, Luttkopf D, Scheurer S, Vieths S, Ebner C, et al. Bet v 1142-156 is the dominant T-cell epitope of the major birch pollen allergen and important for cross-reactivity with Bet v 1-related food allergens. J Allergy Clin Immunol 2005; 116: 213-219.
11. Holm J, Ferreras M, Ipsen H, Wurtzen PA, Gajhede M, Larsen JN, et al. Epitope grafting, re-creating a conformational Bet v 1 antibody epitope on the surface of the homologous apple allergen Mal d 1. J Biol Chem 2011; 286: 17569-17578.
12. Radauer C, Lackner P, Breiteneder H,. The Bet v 1 fold: an ancient, versatile scaffold for binding of large, hydrophobic ligands. BMC Evol Biol 2008; 8: 286.
13. Bucher X, Pichler WJ, Dahinden CA, Helbling A,. Effect of tree pollen specific, subcutaneous immunotherapy on the oral allergy syndrome to apple and hazelnut. Allergy 2004; 59: 1272-1276.
14. van Hoffen E, Peeters KA, van Neerven RJ, van der Tas CW, Zuidmeer L, van Ieperen-van Dijk AG, et al. Effect of birch pollen-specific immunotherapy on birch pollen-related hazelnut allergy. J Allergy Clin Immunol 2011; 127: 100-101.
15. Herrmann D, Henzgen M, Frank E, Rudeschko O, Jager L,. Effect of hyposensitization for tree pollinosis on associated apple allergy. J Investig Allergol Clin Immunol 1995; 5: 259-267.
16. Shamji MH, Wilcock LK, Wachholz PA, Dearman RJ, Kimber I, Wurtzen PA, et al. The IgE-facilitated allergen binding (FAB) assay: validation of a novel flow-cytometric based method for the detection of inhibitory antibody responses. J Immunol Methods 2006; 317: 71-79.
17. Chirumbolo S,. Basophil activation test in allergy: time for an update? Int Arch Allergy Immunol 2012; 158: 99-114.
18. Negi SS, Braun W,. Automated detection of conformational epitopes using phage display Peptide sequences. Bioinform Biol Insights 2009; 3: 71-81.
19. Mutschlechner S, Egger M, Briza P, Wallner M, Lackner P, Karle A, et al. Naturally processed T cell-activating peptides of the major birch pollen allergen. J Allergy Clin Immunol 2010; 125: 711-718, 718. e711-718 e712.
20. Oezguen N, Zhou B, Negi SS, Ivanciuc O, Schein CH, Labesse G, et al. Comprehensive 3D-modeling of allergenic proteins and amino acid composition of potential conformational IgE epitopes. Mol Immunol 2008; 45: 3740-3747.
21. Braden BC, Cauerhff A, Dall'Acqua W, Fields BA, Goldbaum FA, Malchiodi EL, et al. Structure and thermodynamics of antigen recognition by antibodies. Ann N Y Acad Sci 1995; 764: 315-327.
22. Davies DR, Padlan EA, Sheriff S,. Antibody-antigen complexes. Annu Rev Biochem 1990; 59: 439-473.
23. Fraczkiewicz R, Braun W,. Exact and efficient analytical calculation of the accessible surface areas and their gradients for macromolecules. J Comput Chem 1998; 19: 319-333.
24. Mobs C, Slotosch C, Loffler H, Jakob T, Hertl M, Pfutzner W,. Birch pollen immunotherapy leads to differential induction of \regulatory T cells and delayed helper T cell immune deviation. J Immunol 2010; 184: 2194-2203.
25. Shamji MH, Ljorring C, Francis JN, Calderon MA, Larche M, Kimber I, et al. Functional rather than immunoreactive levels of IgG4 correlate closely with clinical response to grass pollen immunotherapy. Allergy 2012; 67: 217-226.
26. Van Milligen FJ, Craig S, Rogers BL, Van Swieten P, Aalberse RC,. Differences between specificities of IgE and IgG4 antibodies: studies using recombinant chain 1 and chain 2 of the major cat allergen Felis domesticus (Fel d) I. Clin Exp Allergy 1995; 25: 247-251.
27. Niederberger V, Reisinger J, Valent P, Krauth MT, Pauli G, van Hage M, et al. Vaccination with genetically modified birch pollen allergens: immune and clinical effects on oral allergy syndrome. J Allergy Clin Immunol 2007; 119: 1013-1016.
28. Pree I, Reisinger J, Focke M, Vrtala S, Pauli G, van Hage M, et al. Analysis of epitope-specific immune responses induced by vaccination with structurally folded and unfolded recombinant Bet v 1 allergen derivatives in man. J Immunol 2007; 179: 5309-5316.
29. Tiwari R, Negi SS, Braun B, Braun W, Pomes A, Chapman MD, et al. Validation of a phage display and computational algorithm by mapping a conformational epitope of Bla g 2. Int Arch Allergy Immunol 2012; 157: 323-330.
30. Lebecque S, Dolecek C, Laffer S, Visco V, Denepoux S, Pin JJ, et al. Immunologic characterization of monoclonal antibodies that modulate human IgE binding to the major birch pollen allergen Bet v 1. J Allergy Clin Immunol 1997; 99: 374-384.
31. Gieras A, Cejka P, Blatt K, Focke-Tejkl M, Linhart B, Flicker S, et al. Mapping of conformational IgE epitopes with peptide-specific monoclonal antibodies reveals simultaneous binding of different IgE antibodies to a surface patch on the major birch pollen allergen, Bet v 1. J Immunol 2011; 186: 5333-5344.
32. Dall'Antonia F, Gieras A, Devanaboyina SC, Valenta R, Keller W,. Prediction of IgE-binding epitopes by means of allergen surface comparison and correlation to cross-reactivity. J Allergy Clin Immunol 2011; 128: 872-879.
33. Hecker J, Diethers A, Schulz D, Sabri A, Plum M, Michel Y, et al. An IgE epitope of Bet v 1 and fagales PR10 proteins as defined by a human monoclonal IgE. Allergy 2012; 67: 1530-1537.
34. Ball T, Sperr WR, Valent P, Lidholm J, Spitzauer S, Ebner C, et al. Induction of antibody responses to new B cell epitopes indicates vaccination character of allergen immunotherapy. Eur J Immunol 1999; 29: 2026-2036.
35. Vickery BP, Lin J, Kulis M, Fu Z, Steele PH, Jones SM, et al. Peanut oral immunotherapy modifies IgE and IgG(4) responses to major peanut allergens. J Allergy Clin Immunol 2013; 131: 128-134.
36. Porollo A, Meller J,. Versatile annotation and publication quality visualization of protein complexes using POLYVIEW-3D. BMC Bioinformatics 2007; 8: 316.